Hanchen Guangyi Secures Over RMB 300 Million in Series B+ Financing to Advance Intelligent Automation in Biological Breeding and Life Sciences

VCBeat has learned that Chengdu Hanchenguangyi Technology Co., Ltd. (hereinafter referred to as “Hanchenguangyi”), a company specializing in intelligent automation for biological breeding and life sciences, recently completed a Series B+ financing round exceeding RMB 300 million. To date, the total amount raised in its Series B financing has surpassed RMB 500 million. This round was co-led by ClearPool Capital and Guotai Junan Innovation Investment, with participation from Daotong Investment, Eightfold Venture Partners, and Guosheng Capital. Existing shareholders Legend Capital and LYFE Capital made additional investments, while Multi-Dimension Capital served as the exclusive financial advisor for this round. The proceeds will be primarily used for new product development in biological breeding and life sciences, market expansion, overseas business development, and team building, further strengthening Hanchenguangyi’s product and market layout and brand influence in these fields, and helping to drive the intelligent automation process across various sectors of biological breeding and life sciences.

 Corporate Headquarters Building

Hanchen Guangyi officially commenced operations in 2016. Focusing on intelligent automation for life sciences, it has become a leading platform enterprise in China for high-end equipment and comprehensive solutions in biological breeding, as well as in the fields of intelligent automation for scientific research and molecular diagnostics. Since its inception, the team has pursued independent research and development (R&D) of core foundational technologies. Through years of continuous accumulation and refinement, it has established full-stack self-developed technical capabilities encompassing both software and hardware. Its product line covers fully automated intelligent equipment, along with supporting reagents and consumables, based on various molecular detection methodologies and diverse sample processing methods. The company has expanded into multiple other life science experimental domains, with its products widely applied in industries such as modern agriculture, scientific research, and in vitro diagnostics. Particularly in the field of biological breeding, Hanchen Guangyi has achieved installation and large-scale adoption by nearly one hundred benchmark customers. This helps downstream clients improve experimental efficiency, reduce costs, and ensure standardized, controllable processes, thereby freeing researchers from tedious experimental procedures to focus on truly creative and investigative work.

“Seeds are the chips of agricultural development.” Seed security serves as the cornerstone for ensuring national food security. Since the No. 1 Central Document called for winning the turnaround battle in the seed industry and overcoming bottleneck technologies in germplasm resources, seed security has gradually been elevated to a strategic level of national security. With continuous major breakthroughs in global biological breeding technologies, coupled with the successive introduction of supporting domestic regulations and policies, the issuance of multiple biosafety certificates, and the launch of pilot programs for the industrialization of seed industry innovations, the “last mile” of industrializing biological breeding technologies in China is being rapidly cleared. To do a good job, one must first sharpen one’s tools; core biological breeding equipment is the “photolithography machine” of the biological breeding industry, yet the domestic market has long been monopolized by imported brands.

Since its establishment, Chengdu Hanchenguangyi Technology Co., Ltd. has been dedicated to the research and development of biological breeding equipment, successfully breaking the monopoly of imported devices. The company has launched a full stack of equipment and solutions with independent intellectual property rights, based on mainstream molecular detection technologies such as PCR and sequencing. These offerings include the industry-leading high-throughput genotyping system, fully automated multifunctional gene detection system, and fully automated nucleic acid concentration detection and normalization workstation. Additionally, the company has successfully delivered multiple unmanned smart laboratory production lines. These products and solutions are widely applied in the biological breeding of major crops, high-end vegetables, fruits, livestock, and poultry within modern agriculture, facilitating applications such as variety and strain identification, germplasm resource conservation and exploration, marker-assisted breeding, and genomic selection breeding.

High-End Intelligent Automated Equipment and Smart Laboratory Solutions for Biological Breeding

Building on its successful expansion in the biological breeding market, Chengdu Hanchenguangyi Technology Co., Ltd. has leveraged its self-developed core technology platform to enter the IVD molecular diagnostics sector, focusing on the development of high-end intelligent automated molecular diagnostic equipment. The company has successfully developed a fully automated molecular diagnostic all-in-one system that leads domestically and has obtained Class III medical device certification. Furthermore, the company has independently developed an extraction and library preparation all-in-one system, along with various sample pre-processing devices, filling the gap for domestic brands in these equipment categories. It is actively expanding the application of molecular diagnostic technologies in niche areas such as pathogen detection, early cancer screening, precision medicine, and drug R&D. Moreover, the company has made strategic layouts in intelligent automation fields including microbial detection and applications, as well as chemical synthesis, with multiple products and projects currently under research, development, and implementation.

 GenePrecision 2200: A Desktop High-Throughput Molecular Diagnostics Laboratory

Obtained Class III Medical Device Registration Certificate

As an intelligent automation platform enterprise in the life sciences sector, following the completion of this round of financing, Hanchen Guangyi will, on one hand, continue to intensify its efforts to expand its product portfolio and actively build a comprehensive intelligent automation data generation infrastructure platform for biological breeding, providing customers with end-to-end, one-stop intelligent automation solutions; on the other hand, it will continuously iterate its molecular diagnostics products to meet the increasingly diverse needs of medical testing scenarios, while actively expanding into fields such as drug discovery, synthetic biology, and chemical synthesis.

Chengdu Hanchenguangyi Technology Co., Ltd. will remain true to its original mission of “Empowering Life Sciences: Achieving the Extraordinary through Simplicity.” By continuously refining its team around its core technology platforms, the company will deepen its engagement in the life sciences sector, establish a strong foothold in China while expanding globally, and drive the intelligent automation and smart upgrading of global life sciences through China-led innovation, thereby creating value for customers worldwide.

Dr. Li Bin, Founder of Qingchi CapitalStatement: Hanchen Guangyi is a rare domestic platform company capable of providing core equipment and comprehensive solutions in both biological breeding and molecular diagnostics. Led by its founder, Dr. Zhang Han, the team has successfully broken the monopoly of imported equipment, particularly in the field of molecular breeding. By focusing on the specific needs of the local seed industry, the company continuously iterates and launches equipment solutions better suited to the requirements of domestic breeding enterprises. Qingchi Capital is honored to partner with Hanchen Guangyi during its rapid growth phase, supporting the company’s efforts to advance the localization and iterative upgrading of molecular breeding tools, thereby aligning with the national strategy for leapfrog development of the modern seed industry. We also look forward to the company’s continued advancements in molecular diagnostics to meet the increasingly diverse demands of medical testing scenarios.

Ms. Jiang Wei, Chairman of Guotai Junan Innovation InvestmentChengdu Hanchenguangyi Technology Co., Ltd. is a leading provider of intelligent automation products and solutions for the life sciences industry, with significant market advantages in modern agriculture, in vitro diagnostics (IVD), and scientific research. Leveraging this financing opportunity, both parties aim to strengthen their strategic partnership, fully utilize Guotai Junan’s professional investment and comprehensive service capabilities, and actively support the company in accelerating market expansion, broadening the boundaries of innovation, and consolidating innovative momentum, with the goal of becoming a world-class enterprise at an early stage.

Mr. Sun Qi, Founding Partner of DaoTong InvestmentStatement: The transformation driven by automation, digitalization, and intelligence is fundamentally reshaping the life sciences industry and enhancing overall industrial efficiency. As an innovation driver in this sector, we are highly optimistic about Chengdu Hanchenguangyi Technology Co., Ltd.’s ability to address current challenges in the seed industry, such as low testing efficiency and insufficient throughput. This will accelerate the iterative upgrading of breeding detection technologies, thereby meeting the future demands of agricultural product development and breeding science. Meanwhile, we also look forward to the company’s further expansion into the downstream market of medical diagnostics, improving the efficiency of clinical testing.

Mr. Zhou Quan, Managing Director at Legend CapitalStatement: Congratulations to the company on completing a new round of financing, and welcome to our new shareholder partners! Since Legend Capital’s previous investment, the company has achieved significant commercialization progress by leveraging its extensive pool of scarce talent and accumulated expertise in the field of high-end life science automation. This additional investment is expected to accelerate the company’s growth in tandem with the rapidly expanding downstream markets for biological breeding and medical testing, thereby empowering further automation upgrades across the life sciences sector in the future.

Mr. Guo Zhenjun, Vice President of Investment at LYFE CapitalIt stated: Since investing in Chengdu Hanchenguangyi Technology Co., Ltd., the company has remained true to its original mission, persisting in the research, development, and manufacturing of upstream life science tools. By creating value for customers, it has earned industry reputation and recognition, while the team has strengthened its technical expertise through continuous mass production. Building on a solid foundation of technology and products, the company has gained recognition from well-known clients in Europe and South America, and is actively expanding its overseas market presence further. We remain optimistic about the company’s performance in both domestic and international markets.

Headquartered in Hong Kong and Shanghai, Lake Bleu Capital is an investment platform focused on the healthcare sector, with assets under management totaling billions of US dollars. Its secondary market USD fund is one of the longest-established healthcare-focused secondary market funds in Asia. Lake Bleu Capital is also active in private equity investments within the Asian healthcare industry, having successfully invested in over 60 outstanding healthcare companies. The firm provides diverse value-added services to its portfolio companies, supporting them in capital operations and business collaborations.

Guotai Junan Innovation Investment Co., Ltd. (hereinafter referred to as “Guotai Junan Innovation Investment”) is the sole wholly-owned private equity investment management subsidiary under Guotai Junan Securities. It is responsible for managing a diverse range of alternative assets, including private equity, special opportunities, and new infrastructure, with assets under management exceeding RMB 60 billion. Adhering to technology-driven innovation as its core guide, the company is committed to supporting the implementation of national strategies and the growth of the real economy.The company focuses primarily on four key sectors: emerging technologies, biopharmaceuticals, green development, and consumer livelihoods. It has established a core business layout centered on “fund-of-funds + industrial funds,” and developed alternative investment lines such as urban renewal, new infrastructure, and special opportunities. Leveraging rigorous closed-loop management across the entire investment lifecycle—fundraising, investing, managing, and exiting—as well as a professional team, the company continuously creates value for its partners and stakeholders.Committed to building an excellent, rigorous, and professional investment research system and enhancing comprehensive, full-cycle operational capabilities, the company strives to create sustainable, long-term, and stable value growth for global investors. It remains dedicated to cultivating high-growth, high-quality enterprises with strong technological and innovative DNA. By providing capital and innovative investment solutions, the company helps outstanding entrepreneurs maximize their potential, drives the overall development of the industries in which its portfolio companies operate, and fulfills its mission of serving the nation through finance.

Daotong Investment focuses on forward-looking medical innovation technologies and serves as the early-stage exclusive investor for multiple first-in-China technology projects. Its portfolio includes venture capital funds, as well as angel funds in the Yangtze River Delta and the Greater Bay Area. The core team members all come from the healthcare industry, having successfully incubated early-stage startups and founded or managed publicly listed companies with market capitalizations exceeding RMB 10 billion. Adhering to the principle of being not only a value discoverer but also a value creator, Daotong Investment has received numerous accolades, including Top 100 VC Firms and Top 20 Medical Device Investors by China Venture. Selected investment cases include Landin Medicine, Deepwise Healthcare, Hannuo Medical, Triastek, and Heyuan Biologics.

Xunzheng Venture Capital is an industrial private equity investment manager, specializing in full-industry-chain investments, mergers and acquisitions, and asset transactions in specific niche sectors underpinned by biological and chemical technologies.

Guosheng Capital, a state-owned industrial investment firm rooted in the Chengdu Tianfu International Bio-town, is dedicated to serving the global development of innovative life sciences. It has established a synergistic ecosystem of nine parent-subsidiary industry funds, with a total scale exceeding RMB 10 billion. To date, it has completed investments in more than 70 outstanding enterprises in the healthcare sector, covering five key areas: modern biopharmaceuticals, innovative chemical drugs, high-performance medical devices, professional outsourcing services, and health services. Adhering to the model of “government guidance + market logic + specialized operations,” Guosheng Capital is committed to becoming China’s most influential comprehensive financial service provider in the industry. The firm has received numerous accolades, including Top 10 Best Emerging VC Firms in China (CVCRI 2021), Top 10 Most Promising Venture Capital Firms in China (China Venture 2021), 2022 Chengdu New Economy Venture Capital Outstanding Contribution Award, Top 10 Dark Horse Investment Firms in Healthcare and Life Sciences (LPCLUB 2022), Top 30 Emerging Government-Guided Funds for Institutional Soft Power (FOFWEEKLY 2023), Top 20 Institutions for Service Empowerment and Soft Power (FOFWEEKLY 2023), and Top 100 Venture Capital Firms Most Preferred by Entrepreneurs (36Kr 2023).

Legend Capital was established in April 2001 and is a leading professional investment firm in China, specializing in early-stage venture capital and growth-stage private equity investment. Over the past two decades, Legend has adhered to international best practices, successfully completed full management cycles for multiple funds, and delivered outstanding and sustainable fund performance. To date, it has invested in more than 600 companies, with 108 achieving exits through initial public offerings (IPOs) on various global capital markets and nearly 100 exiting via mergers and acquisitions. Its portfolio includes world-class enterprises such as iFlytek, Contemporary Amperex Technology Co., Limited (CATL), WuXi AppTec, and Pharmaron, as well as numerous national-level “Specialized, Refined, Differential, and Innovative” (SRDI) Little Giants and manufacturing single champions, thereby building rich industrial resources. True to its original mission, Legend Capital leverages capital and managerial expertise to foster corporate innovation and growth, drive industrial progress, and promote social development. While delivering strong financial returns, the firm actively fulfills its social responsibilities, striving for sustainable and high-quality development.

LYFE Capital is a globally leading healthcare investment platform. We firmly believe that “healthcare knows no borders,” and every investment decision we make is dedicated to advancing biomedical progress and addressing unmet clinical needs worldwide. Leveraging our platform’s extensive investment management expertise and global industry resources, LYFE Capital creates value for its portfolio companies. Our integrated international investment team provides comprehensive support to cutting-edge enterprises at all stages, helping entrepreneurs fully realize their growth potential in the global market.